Literature DB >> 26116823

Long tails, short telomeres: Dyskeratosis congenita.

Hemanth Tummala1, Amanda J Walne1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26116823      PMCID: PMC4546437          DOI: 10.18632/oncotarget.4388

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


× No keyword cloud information.
Dyskeratosis congenita (DC) is an inherited life threatening bone marrow failure syndrome [1]. The name dyskeratosis comes from the classic triad of clinical features nail dystrophy, abnormal skin pigmentation and leucoplakia in patients with DC. However the mortality in DC is primarily due to bone marrow failure and other complications such as pulmonary fibrosis, liver cirrhosis and early onset of cancer. DC is genetically heterogeneous and harbors constitutional mutations in key genes (DKC1, TERC, TERT, NOP10, NHP2, TINF2, TCAB1, CTC1, RTEL1 and ACD) that are involved in telomere maintenance. In short, telomere maintenance is dependent on the catalytic function of telomerase (TERC-RNA component of telomerase and TERT-telomerase reverse transcriptase), telomerase stability (DKC1-dyskerin, NOP10-nucleolar protein 10 homolog and NHP2-non histone ribonucleoprotein 2 homolog), telomerase recruitment (TINF2-TRF1-interacting nuclear protein 2 and ACD-adeno cortical dysplasia homologue aka TPP1), telomerase trafficking (TCAB1-telomerase cajal body 1), telomerase docking (CTC1-conserved telomere maintenance component 1) and telomere replication (RTEL1-regulator of telomere length 1). DC patients carrying mutations in these genes possess critically short telomeres and an abnormal DNA damage response, causing selective exhaustion of cells in tissues with rapid turnover such as the bone marrow [1]. Challenges remain to understand the diverse spectrum of disease aetiology in DC. In addition the genetic characterisation of clinical cases to date accounts only about two thirds of the families in our DC registry in London. In our latest work published in The Journal of Clinical Investigation, we describe the first constitutional biallelic mutations in the poly(A)-specific ribonuclease (PARN) gene in a subgroup of patients with severe DC [2]. These patients have very short telomeres but there had been no previous connection reported between PARN and telomere biology. PARN is an essential deadenylase enzyme that is involved in the control of mRNA stability and turnover. Specifically it trims poly(A) tails of mRNA to exert translational silencing for a large number of genes/transcripts. This is considered to be an important function in the regulation of several key cellular pathways including nonsense mediated RNA decay (NMD) and the DNA damage response. In our study we identified PARN deficiency, abnormal p53 regulation, G2/M phase cell cycle arrest and cell death upon DNA damage in patient cells harboring biallelic PARN mutations. PARN targets a discrete set of mRNAs for degradation in non-stress conditions, which includes p53 [3]. Upon DNA damage PARN binds to the accumulated p53 and other tumour suppressor proteins Cstf(50) – cleavage stimulation factor and BARD1-BRCA1 associated ring domain protein 1) to regulate nuclear deadenylation. Hence PARN activity is tightly controlled under different cellular conditions. What we have shown [2] is that PARN deficient patient cells clearly exhibited a decrease in the stability of several key telomere maintenance genes (DKC1, TERF1, RTEL1 and TERC). However the question still remains as to how PARN deficiency specifically leads to telomere attrition in these patients with severe DC. A recent study published in Nature Genetics reported heterozygous mutations in PARN associated with telomere attrition in patients with idiopathic pulmonary fibrosis [5]. This independent study, based on a different cohort of patients, also indicates a role for PARN in telomere maintenance. The authors of this study speculated that haploinsufficiency of PARN may cause telomere shortening through down regulation of human TERC [4]. However lessons from PARN deadenylase targets may imply a direct role in telomere maintenance [5]. For example, PARN trims oligoadenylated tails of H/ACA-box snoRNAs [5]. As TERC being an H/ACA-box snoRNA, and known to be oligoadenylated in a small fraction of the total TERC pool in human cells [6], it is therefore conceivable that PARN deficiency could result in accumulation of immature oligoadenylated TERC fraction. It is also notable that TERC associates with dyskerin (encoded by DKC1), and mutations in DKC1 identified in DC patients exhibit low levels of TERC. We observed a decrease in DKC1 transcript as well as dyskerin protein levels in patient cells with biallelic PARN mutations [2]. Furthermore, PARN knockdown studies in a heterologous cell system revealed a decrease in DKC1 transcript stability after actinomycin D treatment. Hence reduction in TERC upon PARN deficiency could be a consequence of insufficient dyskerin. PARN deficiency could also impact on telomere maintenance via Cajal bodies, sites for telomerase trafficking and assembly, since depletion of PARN results in reduced size and number of Cajal bodies in human cells [5]. Finally a direct association of PARN to telomeres is also a possibility as it interacts with UPF1 – eukaryotic up-frameshift 1, a key NMD factor that localises to telomeres and regulates the polyadenylated telomeric repeat containing RNA (TERRA) [7]. In conclusion, it has been established that PARN deadenylation function is important in telomere biology. Irrespective of the precise mechanism(s), PARN mutations link the basic deadenylation pathway to telomeropathies such as idiopathic pulmonary fibrosis and dyskeratosis congenita.
  7 in total

1.  Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends.

Authors:  Claus M Azzalin; Patrick Reichenbach; Lela Khoriauli; Elena Giulotto; Joachim Lingner
Journal:  Science       Date:  2007-10-04       Impact factor: 47.728

2.  Maturation of mammalian H/ACA box snoRNAs: PAPD5-dependent adenylation and PARN-dependent trimming.

Authors:  Heike Berndt; Christiane Harnisch; Christiane Rammelt; Nadine Stöhr; Anne Zirkel; Juliane C Dohm; Heinz Himmelbauer; Joao-Paulo Tavanez; Stefan Hüttelmaier; Elmar Wahle
Journal:  RNA       Date:  2012-03-22       Impact factor: 4.942

3.  Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita.

Authors:  Hemanth Tummala; Amanda Walne; Laura Collopy; Shirleny Cardoso; Josu de la Fuente; Sarah Lawson; James Powell; Nicola Cooper; Alison Foster; Shehla Mohammed; Vincent Plagnol; Thomas Vulliamy; Inderjeet Dokal
Journal:  J Clin Invest       Date:  2015-04-20       Impact factor: 14.808

4.  Positive and negative feedback loops in the p53 and mRNA 3' processing pathways.

Authors:  Emral Devany; Xiaokan Zhang; Ji Yeon Park; Bin Tian; Frida Esther Kleiman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

Review 5.  Unraveling the pathogenesis of Hoyeraal-Hreidarsson syndrome, a complex telomere biology disorder.

Authors:  Galina Glousker; Fabien Touzot; Patrick Revy; Yehuda Tzfati; Sharon A Savage
Journal:  Br J Haematol       Date:  2015-05-04       Impact factor: 6.998

6.  Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening.

Authors:  Bridget D Stuart; Jungmin Choi; Samir Zaidi; Chao Xing; Brody Holohan; Rui Chen; Mihwa Choi; Pooja Dharwadkar; Fernando Torres; Carlos E Girod; Jonathan Weissler; John Fitzgerald; Corey Kershaw; Julia Klesney-Tait; Yolanda Mageto; Jerry W Shay; Weizhen Ji; Kaya Bilguvar; Shrikant Mane; Richard P Lifton; Christine Kim Garcia
Journal:  Nat Genet       Date:  2015-04-13       Impact factor: 41.307

7.  3' terminal diversity of MRP RNA and other human noncoding RNAs revealed by deep sequencing.

Authors:  Katherine C Goldfarb; Thomas R Cech
Journal:  BMC Mol Biol       Date:  2013-09-21       Impact factor: 2.946

  7 in total
  1 in total

1.  A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition.

Authors:  Clemens Stockklausner; Simon Raffel; Julia Klermund; Obul Reddy Bandapalli; Fabian Beier; Tim H Brümmendorf; Friederike Bürger; Sven W Sauer; Georg F Hoffmann; Holger Lorenz; Laura Tagliaferri; Daniel Nowak; Wolf-Karsten Hofmann; Rebecca Buergermeister; Carolin Kerber; Tobias Rausch; Jan O Korbel; Brian Luke; Andreas Trumpp; Andreas E Kulozik
Journal:  Aging (Albany NY)       Date:  2015-11       Impact factor: 5.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.